Standardizing utilization of biomarkers in diagnosis and management of acute cardiac syndromes.
Publications on the development and use of myocardial markers have exploded in the decade of the 1990s. According to subscriptions to proficiency testing surveys, enzymatic measurement of creatine kinase and lactate dehydrogenase isoenzymes have largely been replaced by CK-MB mass immunoassays. Laboratories reporting use of myoglobin and cardiac troponin have increased tremendously over the past few years. In this field of medicine where there have been dramatic changes, development of consensus guidelines can be helpful to provide assistance to clinicians and laboratorians as to how they can make the best use of new cardiac markers for clinical practice.
Valdes
R
R
Department of Pathology, University of Louisville School of Medicine, KY 40292, USA. rvaldes@louisville.edu
Jortani
S A
SA
D015415:Biomarkers / Q000097:blood*; D009202:Cardiomyopathies / Q000097:blood / Q000175:diagnosis* / Q000628:therapy; D003402:Creatine Kinase / Q000097:blood; D006801:Humans; D007527:Isoenzymes; D007770:L-Lactate Dehydrogenase / Q000097:blood; D014336:Troponin / Q000097:blood
D015415:Biomarkers; D007527:Isoenzymes; D014336:Troponin; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase